Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar

Publication
Article
BioPharm InternationalBioPharm International-02-01-2002
Volume 15
Issue 2
Pages: 38-42

By Tom Brody, DNAX Research Institute, pp. 38-42. Early sale or offers to sell an invention may result in the rejection of a patent application under 35 U.S.C. 102(b). Such a rejection is called "the on-sale bar," and it permanently prevents patenting of an invention.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Content
© 2025 MJH Life Sciences

All rights reserved.